|
Match
|
Document |
Document Title |
|
|
7612188 |
Modified vitamin K. dependent polypeptides
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot...
|
|
|
7608696 |
IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
This invention encompasses antibodies specific for IBC-1 (Invasive Breast Cancer-1), methods for diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions, methods of...
|
|
|
7605232 |
Hydrogels for protein concentration
A method of concentrating proteins from whole blood comprising exposing whole blood to covalently crosslinked hydrogel to remove water from the blood into the hydrogel to thereby concentrate the...
|
|
|
7598356 |
Method for purifying a protein of the cystine-knot superfamily
The present invention relates to a two-step method for isolating proteins from the cystine-knot superfamily based on dye ligand affinity chromatography and reversed-phase chromatography....
|
|
|
7598352 |
Method of identifying polypeptide monobodies which bind to target proteins and use thereof
A method of identifying a polypeptide monobody having target protein binding activity, said method comprising: providing a host cell comprising (i) a reporter gene under control of a 5′...
|
|
|
7598351 |
Antibody and use thereof
The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2...
|
|
|
7598051 |
Compositions and methods for the therapy and diagnosis of ovarian cancer
Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic...
|
|
|
7597882 |
Protein crosslinkers, crosslinking methods and applications thereof
Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the...
|
|
|
7582725 |
Agents, which inhibit apoptosis in cells that are involved in wound healing
The invention relates to the use of substances as a fundamental constituent in wound healing agents. The invention is characterised in that said substances bond to either IAP and/or integrin α v...
|
|
|
7576190 |
FGF-21 fusion proteins
The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a...
|
|
|
7572890 |
Recombinant human mannan-building proteins
Recombinant Human Mannan-Binding Proteins (rhMBP) having physiological activities which are substantially identical to those offered by Human Mannan-Binding Proteins (hMBP), as well as, in...
|
|
|
7560242 |
Metadherin polypeptides, encoding nucleic acids and methods of use
Metadherin, a protein that controls metastasis, and variants of metadherin are described. DNA sequences encoding the same and methods of production are described. Therapies involving the...
|
|
|
7557188 |
Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide
Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.
|
|
|
7550568 |
Monoclonal antibodies to human high molecular weight-melanoma associated antigen
The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.
|
|
|
7501117 |
Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes...
|
|
|
7498305 |
Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that...
|
|
|
7498130 |
Method of reducing viral load
Methods of activating ATIII in situ in a blood product are disclosed, as is the use of such methods and blood products in treating infectious diseases, inflammatory disorders and diseases or...
|
|
|
7456148 |
Method of producing an anticoagulation effect
A method for producing an anticoagulation effect in a blood coagulation assay, said method comprising contacting a sample of blood with an effective amount of apolipoprotein CIII or fragment,...
|
|
|
7455970 |
Mutation associated with strokes
The present invention relates to a method of identifying a subject predisposed to ischemic stroke. The method includes the step of identifying a mutation in the subject that reduces the release...
|
|
|
7452539 |
Stabilizing polypeptides which have been exposed to urea
Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea.
|
|
|
7445903 |
Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis
The invention concerns citrulline polypeptide derived from fibrin useful for diagnosing or treating rheumatoid arthritis.
|
|
|
7390488 |
Compositions and methods for producing vascular occlusion
The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying...
|
|
|
7378393 |
Recombinant anticoagulant proteins
Novel recombinant anticoagulation proteins, methods of their use and methods of their production are described. In particular, recombinant fusions of annexin V (ANV) and Kunitz protease inhibitors...
|
|
|
7358337 |
Assay for low molecular weight heparin
A prothrombin time reagent for determination of low molecular weight heparin in frsh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal...
|
|
|
7354905 |
Prodrugs of thrombin inhibitors
There is provided compounds of formula I,
R 1 O(O)C—CH 2 —(R)Cgl-Aze-Pab-R 2 I
|
|
|
7351524 |
Diagnostics and therapeutics for macular degeneration-related disorders
The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders.
|
|
|
7348411 |
Process for manufacturing fibrin membranes and fibrin membranes obtained according to this process
A process for manufacturing a fibrin membrane from blood plasma that was partially depleted and subjected to coagulation by adding a solution of a physiological coagulating agent, leaving the...
|
|
|
7335467 |
Breast cancer antigens
The invention provides methods for diagnosing cancer including breast cancer, based on the identification of certain breast cancer-associated polypeptides as antigens that elicit immune responses...
|
|
|
7332577 |
Therapeutic human albumin solutions with low prekallikrein activator (PKA) activity and process for obtaining them
The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content...
|
|
|
7320962 |
Hemoactive compositions and methods for their manufacture and use
Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a...
|
|
|
7309774 |
Antiplasmin cleaving enzyme
Human α 2 -antiplasmin (α 2 AP) is the major inhibitor of the proteolytic enzyme plasmin that digests fibrin. Two forms of α 2 AP circulate in human plasma: a 464-residue protein, which we have...
|
|
|
7297680 |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
Disclosed are immortalized human embryonic retina cells, having a nucleic acid sequence encoding an adenoviral E1A protein integrated into the genome of the cells, and further comprising a nucleic...
|
|
|
7288257 |
Diagnosis and treatment of human dormancy syndrome
New methods for diagnosis of human dormancy syndrome are provided. Human dormancy syndrome is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects from which...
|
|
|
7285418 |
Method and kit for the diagnosis of troponin I
The invention provides a method for assaying for troponin I in a sample such as serum, the method comprising a determination of the troponin I concentration in a sample using a standard preparation...
|
|
|
7282567 |
Monoclonal antibody hPAM4
This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding...
|
|
|
7270961 |
In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes
The present invention provides methods of quantitating recent secreted antigen specific antibodies from supernatant of antibody secreting cells (ASC) in vitro culture for evaluation of vaccine or...
|
|
|
7268110 |
Agents for preventing and treating thrombocytopenia
Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient.
|
|
|
7253142 |
Protein solution preparation and method of stabilizing the same
The present invention provides stable protein solution formulations filled in a container made from a hydrophobic resin at least for the part in direct contact with said formulation.
|
|
|
7252824 |
Anti-neovasculature preparations for cancer
Disclosed herein are immunogenic compositions, methods of designing immunogenic compositions, methods of treatment using immunogenic compositions, methods of evaluating cell-mediated immunity...
|
|
|
7247708 |
Modified vitamin K-dependent polypeptides
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot...
|
|
|
7247707 |
Albumin-free factor VIII formulations
A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of...
|
|
|
7238786 |
Monoclonal antibody cPAM4
This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more...
|
|
|
7232888 |
Antibodies against tumor surface antigens
The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity...
|
|
|
7226999 |
Protein C or activated protein C-like molecules
The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention...
|
|
|
7226995 |
Use of C-reactive protein to treat immune complex-mediated renal disease
The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The...
|
|
|
7223844 |
Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes
The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4,...
|
|
|
7220836 |
Dried blood factor composition comprising trehalose
A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.
|
|
|
7220552 |
Bifunctional molecules and their use in the disruption of protein-protein interactions
Bifunctional inhibitor molecules and methods for their use in the inhibition of protein—protein interactions are provided. The subject bifunctional inhibitor molecules are conjugates of a target...
|
|
|
7217796 |
Neutralizing human anti-IGFR antibody
The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing...
|
|
|
7217795 |
Tumor suppressor designated TS10q23.3
A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene...
|